IDEAYA Showcases Darovasertib Data at ESMO 2026
SOUTH SAN FRANCISCO, Calif., July 17, 2026 IDEAYA Biosciences, Inc. has announced that it will present three clinical abstracts...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., July 17, 2026 IDEAYA Biosciences, Inc. has announced that it will present three clinical abstracts...
South San Francisco, California, USA, April 21, 2026 In a significant advancement in precision oncology, IDEAYA Biosciences, Inc. has...
Queensbury, New York, USA, April 6, 2026 ESMO Guideline Inclusion Validates CHEMOSAT Therapy In a major milestone for interventional...
South San Francisco, California, USA | March 22, 2026 IDEAYA Biosciences has announced updated guidance on the anticipated topline...
